- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07753018
Effects of Curcumin-Piperine Supplementation in Fibromyalgia
Evaluation of the Effect of Curcumin and Piperine Supplementation on Clinical Outcome in Fibromyalgia Patients.
The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo.
Participants will:
Be randomly assigned to receive either curcumin and piperine supplements or a placebo.
Attend scheduled clinic visits for clinical assessments and blood sample collection.
Complete study questionnaires before and after treatment time frame.
The primary question the study aim to answer is:
Does Curcumin-piperine supplementation reduce pain intensity by Visual Analog Scale (VAS), compared with placebo?
The secondary questions this study aims to answer are:
Does supplementation improve fibromyalgia disease impact and quality of life? Does supplementation improve inflammatory biomarkers and oxidative stress? Does supplementation improve insulin resistance? Is curcumin and piperine supplementation safe and well tolerated?
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Fibromyalgia (FM) is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive impairment, and mood disorders. Increasing evidence suggests that its pathogenesis is driven by a complex interaction of central sensitization, neuroinflammation, and oxidative stress. Elevated levels of pro-inflammatory cytokines and oxidative stress biomarkers have been linked to pain severity and disease progression. Although current pharmacological therapies can reduce symptoms, their effectiveness is often limited, and they do not adequately address the underlying biological mechanisms.
In addition to inflammation and oxidative stress, insulin resistance (IR) has recently emerged as a potential contributor to fibromyalgia. Several clinical studies have reported higher HOMA-IR values in patients with FM than in healthy individuals, with greater insulin resistance being associated with more severe pain and poorer clinical outcomes. This relationship may be explained by chronic low-grade inflammation, increased oxidative stress, impaired glucose metabolism, and altered central pain processing. These findings suggest that metabolic dysfunction may contribute to symptom persistence and represent an additional therapeutic target in FM.
Curcumin, a natural polyphenol extracted from "Curcuma longa", has attracted considerable interest because of its anti-inflammatory, antioxidant, neuroprotective, and analgesic properties. In addition to reducing inflammatory mediators, oxidative stress, and modulating pain pathways, curcumin has been shown to improve insulin sensitivity and glycemic control, suggesting that it may simultaneously target both the inflammatory and metabolic abnormalities associated with FM.
These findings support the hypothesis that curcumin may improve fibromyalgia by addressing inflammation, oxidative stress, pain sensitization, and metabolic dysfunction. However, current clinical evidence remains limited by small sample sizes and short intervention periods. Furthermore, curcumin's poor oral bioavailability can be markedly enhanced by co-administration with piperine, which increases its intestinal absorption. Therefore, a well-designed randomized controlled trial is needed to evaluate the efficacy and safety of curcumin-piperine supplementation as an adjunctive therapy for patients with fibromyalgia.
A total of 80 fibromyalgia patients will be enrolled in the study. Patients will be stratified according to insulin resistance status (insulin-resistant vs. non-insulin-resistant) followed by permuted block randomization to the study groups. All patients in both groups will receive standard treatment consisting of duloxetine and gabapentin, along with personalized guidance on an anti-inflammatory diet and exercise program.
Participants will be educated about the study and asked to sign a written informed consent before starting the study, assuring that they can withdraw at any time if they want.
The following data will be collected from patient records and by history taking from the patients upon enrollment:
A. Patient demographics including age, gender, weight, height, and body mass index (BMI).
B. Clinical variables including HbA1c, and HOMA-IR, complete blood picture, kidney function tests and liver function tests C. Comorbidities including but not limited to diabetes, hypertension, chronic kidney disease, cardiovascular disease, and immunosuppression.
D. Medical history including previous hospitalizations, surgeries, medication history, and known drug allergies.
E. Medication history including analgesic consumption (dose, frequency, and duration)
The patients will be followed up by weekly phone calls to encourage adherence and to evaluate the incidence and severity of the adverse effects including GIT disturbances or any other undesirable side effects reported by the patients throughout the trial. In addition, complete blood picture, kidney function tests, and liver function tests will be assessed at baseline, after 1 month and by the end of the study (after 3 months).
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Marina W Khalil
- Número de telefone: +201222157176
- E-mail: marina12william@gmail.com
Locais de estudo
-
-
-
Ismailia, Egito, 41511
- Suez Canal University hospitals
-
Contato:
- Rheumatology and Rehabilitation Outpatient Clinic
- Número de telefone: +201277884948
-
Investigador principal:
- marina w khalil, M.Sc candidate
-
Subinvestigador:
- Maha Abd El-Fattah, Associate Professor of Rheumat
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adult women aged ≥18 years.
- Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria.
Exclusion Criteria:
- Diabetic patients (HbA1c ≥ 6.5).
- Patients with chronic inflammatory or autoimmune diseases other than FM.
- Patients allergic to curcumin or piperine.
- Patients receiving other anti-inflammatory medications.
- Severe hepatic or renal impairment.
- Patients receiving anticoagulant medications (e.g., clopidogrel).
- Pregnancy or lactation.
- Participation in another clinical trial
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Group A (Curcumin Group)
The experimental group will receive Organic Nation Curcumin® oral coated tablets, administered once daily for 3 months, containing 1,200 mg of standardized curcumin (95% turmeric extract) combined with 10 mg of piperine (95% black pepper extract), in addition to the standard treatment.
|
The experimental group will receive Organic Nation Curcumin® oral coated tablets, administered once daily for 3 months, containing 1,200 mg of standardized curcumin (95% turmeric extract) combined with 10 mg of piperine (95% black pepper extract).
|
|
Comparador de Placebo: Group B (Placebo Group)
Participants will receive identical-appearing tablets containing inert excipients once daily for 3 months, in addition to the standard treatment.
|
the placebo group will receive matching oral placebo tablet containing inert excipients for the same duration.
The placebo tablets will be identical in appearance, size, color, and packaging to the active supplement to maintain blinding.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Assessment of pain severity measured by the Visual Analog Scale (VAS)
Prazo: 3 months
|
VAS is a self-administered instrument widely used in fibromyalgia research and clinical practice to assess pain intensity and monitor treatment response.
The VAS uses a 10-cm horizontal line anchored by 0 (no pain) and 10 (worst imaginable pain).
It will be measured at baseline, after 1 month, and after 3 months.
|
3 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The Revised Fibromyalgia Impact Questionnaire (FIQR)
Prazo: 3 months
|
is a disease-specific, patient-reported outcome measure designed to assess disease severity and the overall impact of fibromyalgia.
It comprises 21 items grouped into three domains: function (9 items assessing physical activities), overall impact (2 items evaluating the extent to which fibromyalgia interferes with goal achievement and causes a feeling of being overwhelmed), and symptoms (10 items assessing pain, fatigue, sleep quality, stiffness, depression, anxiety, memory, balance, tenderness, and environmental sensitivity).
All items are rated on a 0-10 numeric scale.
The total FIQR score ranges from 0 to 100, with higher scores indicating greater disease impact and symptom severity.
It will be measured at baseline, after 1 month, and after 3 months
|
3 months
|
|
The 36-Item Short Form Health Survey (SF-36)
Prazo: 3 months
|
SF-36 is a validated, self-administered, generic instrument used to assess health-related quality of life in fibromyalgia research by evaluating both physical and mental health status.
It consists of 36 items covering eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health.
Domain scores are transformed to a scale ranging from 0 to 100, where 0 represents the worst and 100 the best perceived health status, and are aggregated into two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
It will be measured at baseline, after 1 month, and after 3 months
|
3 months
|
|
Serum inflammatory biomarkers: IL-6
Prazo: 3 months
|
Collected serum samples will be stored at -80 C until analysis.
Serum IL-6 will be assessed using enzyme-linked immunosorbent assay (ELISA) kits.
It will be measured at the start and end of the study (after 3 months).
|
3 months
|
|
Serum oxidative biomarker: MDA
Prazo: 3 months
|
Collected serum samples will be stored at -80oC until analysis.
Serum MDA will be assessed for each patient using spectrophotometric assay kits.
It will be measured at the start and end of the study (after 3 months).
|
3 months
|
|
Glycemic markers: HOMA-IR
Prazo: 3 months
|
Insulin resistance will be assessed using the HOMA-IR ( fasting insulin × fasting glucose / 405), which is calculated from fasting glucose and fasting insulin levels.
Fasting blood glucose will be measured using an enzymatic colorimetric method, and fasting serum insulin will be determined using ELISA kits.It will be measured at the start and end of the study (after 3 months).
|
3 months
|
|
The Hospital Anxiety and Depression Scale (HADS)
Prazo: 3 months
|
The scale consists of 14 self-reported items, divided equally into two domains: anxiety (HADS-A) and depression (HADS-D).
Each item is rated on a 4-point Likert scale (0-3), yielding subscale scores ranging from 0 to 21, where higher scores indicate greater symptom severity.
A cut-off score of ≥8 on either subscale is considered indicative of clinically relevant anxiety or depression.
Elevated HADS scores in this population have been consistently associated with higher symptom severity, increased pain intensity, poorer sleep quality, reduced quality of life, and functional impairment.
It will be measured at baseline, after 1 month, and after 3 months.
|
3 months
|
|
Incidence and severity of treatment-emergent adverse events
Prazo: 3 months
|
The patients will be followed up by weekly phone calls to evaluate the incidence and severity of the adverse effects including GIT disturbances or any other undesirable side effects.
|
3 months
|
|
Change in alanine aminotransferase (ALT) level
Prazo: 3 months
|
Serum alanine aminotransferase (ALT) level will be assessed at baseline and after 3 months.
ALT will be reported in unit per liter (U/L)
|
3 months
|
|
Change in aspartate aminotransferase (AST) level
Prazo: 3 months
|
Serum aspartate aminotransferase (AST) level will be assessed at baseline and after 3 months.
AST will be reported in unit per liter (U/L)
|
3 months
|
|
Change in serum creatinine level
Prazo: 3 months
|
Change in serum creatinine level will be assessed at baseline and after 3 months.
Serum creatinine level will be reported in (mg/dL).
|
3 months
|
|
Change in hemoglobin level
Prazo: 3 months
|
Hemoglobin level will be assessed at baseline and after 3 months.
Hemoglobin will be reported in (g\dL).
|
3 months
|
|
Change in white blood cell count
Prazo: 3 Months
|
white blood cell count will be assessed at baseline and after 3 months.
white blood cell count will be reported as thousand cells per microliter
|
3 Months
|
|
Change in platelet count
Prazo: 3 months
|
Platelet count will be assessed at baseline and after 3 months.
Platelet count will be reported as thousand cells per microliter.
|
3 months
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan;15(1):195-218. doi: 10.1208/s12248-012-9432-8. Epub 2012 Nov 10.
- Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020 Nov;16(11):645-660. doi: 10.1038/s41584-020-00506-w. Epub 2020 Oct 6.
- Kia S, Choy E. Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology. Biomedicines. 2017 May 8;5(2):20. doi: 10.3390/biomedicines5020020.
- Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998 May;64(4):353-6. doi: 10.1055/s-2006-957450.
- Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120. doi: 10.1186/ar2783. Epub 2009 Aug 10.
- O'Mahony LF, Srivastava A, Mehta P, Ciurtin C. Is fibromyalgia associated with a unique cytokine profile? A systematic review and meta-analysis. Rheumatology (Oxford). 2021 Jun 18;60(6):2602-2614. doi: 10.1093/rheumatology/keab146.
- Jurado-Priego LN, Cueto-Urena C, Ramirez-Exposito MJ, Martinez-Martos JM. Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies. Biomedicines. 2024 Jul 11;12(7):1543. doi: 10.3390/biomedicines12071543.
- Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Dominguez MP, Castven D, Breuhahn K, Conner EA, Galle PR, Andersen JB, Factor VM, Thorgeirsson SS. Curcumin effectively inhibits oncogenic NF-kappaB signaling and restrains stemness features in liver cancer. J Hepatol. 2015 Sep;63(3):661-9. doi: 10.1016/j.jhep.2015.04.018. Epub 2015 May 1.
- Alikiaii B, Khatib N, Badpeyma M, Hasanzadeh E, Abbasi S, Amini S, Kiani Z, Hassanizadeh S, Iraj Z, Sahebkar A, Majeed A, Bagherniya M. Therapeutic effects of curcumin and piperine combination in critically ill patients with sepsis: a randomized double-blind controlled trial. Trials. 2025 Jun 14;26(1):205. doi: 10.1186/s13063-025-08916-5.
- Vallejo MA, Rivera J, Esteve-Vives J, Rodriguez-Munoz MF; Grupo ICAF. [Use of the Hospital Anxiety and Depression Scale (HADS) to evaluate anxiety and depression in fibromyalgia patients]. Rev Psiquiatr Salud Ment. 2012 Apr-Jun;5(2):107-14. doi: 10.1016/j.rpsm.2012.01.003. Epub 2012 Mar 2. Spanish.
- Uslu EY, Uslu MF, Yildiz S, Tabara MF. Evaluating Oxidative Stress in Fibromyalgia: Diagnostic Utility and Its Relationship with Clinical and Psychological Parameters. Medicina (Kaunas). 2025 Jul 10;61(7):1248. doi: 10.3390/medicina61071248.
- Tunc Karaman S, Huner B, Basat O. The impact of metabolic health on fibromyalgia: insights from insulin resistance and related indexes. Postgrad Med. 2025 Jan;137(1):28-36. doi: 10.1080/00325481.2024.2439244. Epub 2024 Dec 10.
- Terkawi AS, Tsang S, AlKahtani GJ, Al-Mousa SH, Al Musaed S, AlZoraigi US, Alasfar EM, Doais KS, Abdulrahman A, Altirkawi KA. Development and validation of Arabic version of the Hospital Anxiety and Depression Scale. Saudi J Anaesth. 2017 May;11(Suppl 1):S11-S18. doi: 10.4103/sja.SJA_43_17.
- Shayan NA, Arslan UE, Hooshmand AM, Arshad MZ, Ozcebe H. The Short Form Health Survey (SF-36): translation and validation study in Afghanistan. East Mediterr Health J. 2020 Aug 25;26(8):899-908. doi: 10.26719/emhj.20.064.
- Shahid, A., Wilkinson, K., Marcu, S., & Shapiro, C. M. (2011). Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F). In STOP, THAT and One Hundred Other Sleep Scales (pp. 399-402). Springer New York. https://doi.org/10.1007/978-1-4419-9893-4_100
- San Mauro Martin, I., López Oliva, S., Collado Yurrita, L., Sanz Rojo, S., & Garicano Vilar, E. (2019). Anti-inflammatory and antioxidant feeding and supplementation may serve as adjuvants in women with fibromyalgia. Journal of Nutrition & Intermediary Metabolism, 15, 3-9. https://doi.org/10.1016/j.jnim.2018.11.002
- Sahebkar, A., Serban, M. C., Ursoniu, S., & Banach, M. (2015). Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. In Journal of Functional Foods (Vol. 18, pp. 898-909). Elsevier Ltd. https://doi.org/10.1016/j.jff.2015.01.005
- Rossello Aubach L, Fornos Roca X, Fernandez Alvarez ME. Effects of Coenzyme Q10, Tryptophan, and Magnesium Supplementation on Fatigue in Patients with Fibromyalgia - A Randomized Trial. J Diet Suppl. 2025;22(3):433-444. doi: 10.1080/19390211.2025.2483269. Epub 2025 Mar 28.
- Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem. 2012 Nov;49(Pt 6):580-8. doi: 10.1258/acb.2012.012040. Epub 2012 Oct 4.
- Naghsh N, Musazadeh V, Nikpayam O, Kavyani Z, Moridpour AH, Golandam F, Faghfouri AH, Ostadrahimi A. Profiling Inflammatory Biomarkers following Curcumin Supplementation: An Umbrella Meta-Analysis of Randomized Clinical Trials. Evid Based Complement Alternat Med. 2023 Jan 16;2023:4875636. doi: 10.1155/2023/4875636. eCollection 2023.
- Miranda-Castro S, Aidar FJ, de Moura SS, Marcucci-Barbosa L, Lobo LF, de Assis Dias Martins-Junior F, da Silva Filha R, Vaz de Castro PAS, Simoes E Silva AC, da Gloria de Souza D, da Silva SA, de Castro Pinto KM, de Paula Costa G, Silva AF, Clemente FM, Pereira WVC, Nunes-Silva A. The Curcumin Supplementation with Piperine Can Influence the Acute Elevation of Exercise-Induced Cytokines: Double-Blind Crossover Study. Biology (Basel). 2022 Apr 10;11(4):573. doi: 10.3390/biology11040573.
- Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernandez-Ferreira E, Perez-Tapia SM, Perez-Sanchez G, Garces-Alvarez ME, Aguirre-Cruz L, Velasco-Velazquez MA, Pavon L. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol. 2016 Jan 15;290:22-5. doi: 10.1016/j.jneuroim.2015.11.011. Epub 2015 Nov 26.
- Lopresti AL. Potential Role of Curcumin for the Treatment of Major Depressive Disorder. CNS Drugs. 2022 Feb;36(2):123-141. doi: 10.1007/s40263-022-00901-9. Epub 2022 Feb 7.
- Li Q , Sun J , Mohammadtursun N , Wu J , Dong J , Li L . Curcumin inhibits cigarette smoke-induced inflammation via modulating the PPARgamma-NF-kappaB signaling pathway. Food Funct. 2019 Dec 11;10(12):7983-7994. doi: 10.1039/c9fo02159k.
- Khader S, Hourani MM, Al-Akour N. Normative data and psychometric properties of short form 36 health survey (SF-36, version 1.0) in the population of north Jordan. East Mediterr Health J. 2011 May;17(5):368-74.
- Kahraman T, Ayaz A. Dietary Phytonutrients in Fibromyalgia: Integrating Mechanisms, Biomarkers, and Clinical Evidence-A Narrative Review. Medicina (Kaunas). 2025 Dec 15;61(12):2211. doi: 10.3390/medicina61122211.
- Ilari S, Nucera S, Malafoglia V, Proietti S, Passacatini LC, Caminiti R, Mazza V, Bonaddio A, Oppedisano F, Maiuolo J, Caccamo D, Tafani M, Tomino C, Mollace V, Raffaeli W, Muscoli C. Does Vitamin D Supplementation Impact Fibromyalgia-Related Pain? A Systematic Review and Meta-Analysis. Nutrients. 2025 Oct 15;17(20):3232. doi: 10.3390/nu17203232.
- Ho T, Ryan M, Holle J. Redox reactions in chronic pain: mechanisms and relevance in fibromyalgia. Front Pain Res (Lausanne). 2025 May 13;6:1593908. doi: 10.3389/fpain.2025.1593908. eCollection 2025.
- Guo J, Cao X, Hu X, Li S, Wang J. The anti-apoptotic, antioxidant and anti-inflammatory effects of curcumin on acrylamide-induced neurotoxicity in rats. BMC Pharmacol Toxicol. 2020 Aug 18;21(1):62. doi: 10.1186/s40360-020-00440-3.
- El-Rakabawy OM, Elkholy AA, Mahfouz AA, Abdelsalam MM, El Wakeel LM. Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk. Sci Rep. 2025 Aug 4;15(1):28358. doi: 10.1038/s41598-025-09783-5.
- Gorgani L, Mohammadi M, Najafpour GD, Nikzad M. Piperine-The Bioactive Compound of Black Pepper: From Isolation to Medicinal Formulations. Compr Rev Food Sci Food Saf. 2017 Jan;16(1):124-140. doi: 10.1111/1541-4337.12246. Epub 2016 Nov 22.
- Ghorbani Z, Hekmatdoost A, Mirmiran P. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Int J Endocrinol Metab. 2014 Oct 1;12(4):e18081. doi: 10.5812/ijem.18081. eCollection 2014 Oct.
- Fatima G, Das SK, Mahdi AA. Some oxidative and antioxidative parameters and their relationship with clinical symptoms in women with fibromyalgia syndrome. Int J Rheum Dis. 2017 Jan;20(1):39-45. doi: 10.1111/1756-185X.12550. Epub 2015 Jul 14.
- Elsawy, N., Hassan, M., Ghazala, R., Hamed, R., & Elnemr, R. (2025). Insulin resistance in non-diabetic premenopausal female patients with fibromyalgia: relation to disease characteristics. Egyptian Rheumatology and Rehabilitation, 52(1). https://doi.org/10.1186/s43166-025-00339-z
- Elsaid, N. Y. (2025). Understanding fibromyalgia: A comprehensive review of the literature. The Egyptian Rheumatologist, 47(2), 90-97. https://doi.org/10.1016/j.ejr.2025.02.001
- Ebrahimzadeh A, Abbasi F, Ebrahimzadeh A, Jibril AT, Milajerdi A. Effects of curcumin supplementation on inflammatory biomarkers in patients with Rheumatoid Arthritis and Ulcerative colitis: A systematic review and meta-analysis. Complement Ther Med. 2021 Sep;61:102773. doi: 10.1016/j.ctim.2021.102773. Epub 2021 Aug 31.
- Cordero MD, Alcocer-Gomez E, de Miguel M, Culic O, Carrion AM, Alvarez-Suarez JM, Bullon P, Battino M, Fernandez-Rodriguez A, Sanchez-Alcazar JA. Can coenzyme q10 improve clinical and molecular parameters in fibromyalgia? Antioxid Redox Signal. 2013 Oct 20;19(12):1356-61. doi: 10.1089/ars.2013.5260. Epub 2013 Apr 6.
- Bai KY, Liu GH, Fan CH, Kuo LT, Hsu WH, Yu PA, Chen CL. 12-week curcumin supplementation may relieve postexercise muscle fatigue in adolescent athletes. Front Nutr. 2023 Jan 4;9:1078108. doi: 10.3389/fnut.2022.1078108. eCollection 2022.
- Askari G, Sahebkar A, Soleimani D, Mahdavi A, Rafiee S, Majeed M, Khorvash F, Iraj B, Elyasi M, Rouhani MH, Bagherniya M. The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial. Trials. 2022 Jun 6;23(1):472. doi: 10.1186/s13063-022-06375-w.
- Appelboom, T., & MsciBiost, C. M. (2013). Flexofytol, a Purified Curcumin Extract, in Fibromyalgia and Gout: A Retrospective Study. Open Journal of Rheumatology and Autoimmune Diseases, 03(02), 104-107. https://doi.org/10.4236/ojra.2013.32015
- Abu-Dahab S, AbuRuz SM, Mustafa K, Sarhan Y. Validation of the Arabic version of the revised Fibromyalgia Impact Questionnaire (FIQR_A) on Jordanian females with fibromyalgia. Clin Rheumatol. 2014 Mar;33(3):391-6. doi: 10.1007/s10067-013-2347-7. Epub 2013 Jul 31.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças musculoesqueléticas
- Doenças do Sistema Nervoso
- Doenças Musculares
- Processos Patológicos
- Doenças Neuromusculares
- Doenças Reumáticas
- Doenças Metabólicas
- Distúrbios do Metabolismo da Glicose
- Hiperinsulinismo
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Fibromialgia
- Inflamação
- Resistência a insulina
Outros números de identificação do estudo
- 479
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .